GeneDx Holdings Corp. Warrant (WGSWW)

Multiple health care stocks experienced significant options trading activity, with various bullish and bearish signals across different companies in the sector.

Rosen Law Firm is investigating potential securities claims against GeneDx Holdings Corp. after a Grizzly Research report alleged widespread fraud, causing the stock to drop 6.7%.

GeneDx Holdings (WGS) stock plunged 42.9% despite reporting better-than-expected Q1 revenue and earnings. Investors were disappointed by the smaller-than-usual revenue beat and a decline in test volume. The company raised its full-year revenue guidance, but its valuation appears expensive compared to industry peers.

GeneDx, a leader in genome and exome testing, saw its stock price surge over 2,700% in 2024. The company's strong earnings and revenue growth in Q4 2024 have continued into 2025, with the stock price spiking 47% on Tuesday. However, a recent negative report by Grizzly Research has raised concerns about the company's growth.